还原型谷胱甘肽在预防糖尿病大鼠勃起功能障碍中的研究

目的探讨还原型谷胱甘肽(GSH)在预防糖尿病大鼠勃起功能障碍中的作用。方法通过腹腔注射链脲佐菌素65mg/kg建立糖尿病大鼠模型,然后随机分成DM组和DM+GSH组,DM+GSH组每天肌肉注射GSH200mg/kg。10周后观察大鼠勃起功能,并获取海绵体组织检测其谷胱甘肽、一氧化氮合酶(NOS)与丙二醛(MDA)水平,用TUNEL法检测细胞凋亡。结果成功建立糖尿病大鼠模型。与未注射GSH的DM组相比,DM+GSH组和正常对照组(C组)勃起功能更好,勃起率分别是20%,62.5%和100%。GSH水平DM+GSH组和C组明显比DM组高,其3组含量每克蛋白分别是(75.83±15.62)、(61.47±8.65)和(35.03±12.29)mg(P<0.05);NOS水平在DM+GSH组每毫克蛋白为(133.9±31.9)U,与正常对照组每毫克蛋白为(142.2±31.2)U相当,但较DM组每毫克蛋白为(58.4±18.9)U高(P<0.05);MDA含量在DM组每毫克蛋白为(3.71±0.62)nmol,明显高于正常对照组和DM+GSH组(P<0.05),这两组每毫克蛋白为(2.08±0.34)nmol和(2.44±0.28)nmol;细胞凋亡率在DM组、DM+GSH组和C组的分别是(22.6±3.6)%、(10.8±1.7)%和(7.2±2.1)%(P<0.05)。结论还原型谷胱甘肽对糖尿病大鼠阴茎组织有较好的抗氧化作用,能减少细胞凋亡,对延缓糖尿病性ED的发生有一定的作用。     

中、老年代谢综合征患者的临床特点分析

目的 比较中、老年代谢综合征(MS)患者的临床特点.方法 收集1996～2006年在解放军总医院门诊查体且符合中国人MS诊断标准(CDS)的947例中、老年患者的临床资料.其中老年人679例,中年人268例.分析中、老年患者MS各组分的差异,以及各组分的相关因素等.结果 947例患者中,男性582例(老年423例,中年159例),女性365例(老年256例,中年109例).老年男性患者的年龄大于老年女性(81.5±6.5 vs 74.5±8.8岁,P＜0.01),老年男性的体重指数(BMI)高于中年男性(27.14±2.51 vs 25.98±2.38,P＜0.01).老年患者的空腹、餐后血糖和收缩压均高于同性别的中年患者,而舒张压无显著差异.中年男性的甘油三酯高于老年男性.中年女性的高密度脂蛋白胆固醇高于男性.多元回归分析显示,男女患者空腹血糖均与餐后2h血糖有相关性(男性R2＝0.463,P＜0.05;女性R2＝0.613,P＜0.05).餐后2h血糖与年龄存在相关性(男性,R2＝0.522,P＜0.01;女性R2＝0.716,P＜0.05).收缩压与多种指标均有相关性,男性患者收缩压与年龄(R2＝0.396,P＜0.01)和舒张压(R2＝0.535,P＜0.05)均有相关性;女性患者的收缩压与BMI(R2＝0.557,P＜0.05)、舒张压(R2＝0.434,P＜0.05)、餐后2h血糖(R2＝0.434,P＜0.01)及空腹血糖(R2＝0.473,P＜0.05)均有相关性.Logistic回归分析示年龄(OR=2.1,95%CI:1.3～2.7)、空腹血糖(OR=1.7,95%CI:1.2～3.1)和收缩压(OR=1.4,95%CI:1.2～2.9)是预测代谢综合征组分含量的影响因素.结论 中老年代谢综合征患者的代谢指标有差异,年龄、空腹血糖和收缩压可作为代谢综合征的筛选指标.     

The opposing effects of the flavonoids isoquercitrin and sissotrin, isolated from Pterospartum tridentatum, on oral glucose tolerance in rats

The effect of an aqueous extract of Pterospartum tridentatum on the blood glucose levels of normal Wistar rats was investigated in a situation of oral glucose challenge. The extract at 300 mg/kg showed an antihyperglycaemic effect in the first 30 min after glucose challenge but then the blood glucose levels rose above those of the control group, indicating the presence of compounds with different effects on glucose tolerance. Nine compounds of isoflavone and flavonol skeletons were identified in the extract by HPLC-ESI-MS(n), four of them being identified for the first time in this species. The isoflavone sissotrin and the flavonol derivative, isoquercitrin, were selected for the oral glucose tolerance test. Isoquercitrin (100 mg/kg) showed time-dependent antihyperglycaemic activity by delaying the post-oral glucose load glycaemic peak at 30 min, as did the sodium-dependent glucose transporter inhibitor phloridzin (100 mg/kg). In contrast, sissotrin (100 mg/kg) showed an opposite effect, impairing glucose tolerance. In conclusion, these preliminary results indicate that the effect of the extract on blood glucose may be either antihyperglycaemic or hyperglycaemic. Additionally, as far as is known, these are the first in vivo results on the acute antihyperglycaemic potential of isoquercitrin.     

Incidence of Type 2 diabetes in England and its association with baseline impaired fasting glucose: the Ely study 1990-2000.

AIM: To determine the incidence of Type 2 diabetes and to examine the effect of different cut-points for impaired fasting glucose (IFG) on diabetes incidence. METHODS: Population-based longitudinal study (1990-2000) with clinical, anthropometric and biochemical measurements, including an oral glucose tolerance test (OGTT), in 1040 non-diabetic adults aged 40-69 years at baseline. Baseline glucose status was defined as normoglycaemia < 5.6, IFG-lower 5.6-6.0 and IFG-original 6.1-6.9 mmol/l. The all-IFG group included fasting glucose values of 5.6-6.9 mmol/l. RESULTS: The 10-year cumulative incidence of diabetes was 7.3 per 1000 person-years. Diabetes incidence was 2.4 [95% confidence interval (CI) 1.2, 4.8], 6.2 (4.0, 9.8) and 17.5 (12.5, 24.5) per 1000 person-years in those with normoglycaemia, IFG-lower and IFG-original, respectively. Compared with normoglycaemia, the age/sex-adjusted risk [hazard ratio (HR) and 95% CI] for incident diabetes was greatest in the IFG-original category (HR 6.9; 3.1, 15.2) and increased to a lesser degree in the IFG-lower (HR 2.5; 1.1, 5.7) and all-IFG categories (HR 4.1; 1.9, 8.7). When adjusted for confounding factors, the magnitude and direction of associations persisted, with HR 1.9, 4.4 and 2.9, for the categories IFG-lower, IFG-original and all-IFG, respectively. CONCLUSIONS: Diabetes incidence is more strongly related to IFG defined as fasting glucose between 6.1 and 6.9 mmol/l than to the lower category of 5.6-6.0 mmol/l, or entire range of 5.6-6.9 mmol/l. Future studies should examine the association of IFG with cardiovascular outcomes, but for diabetes risk our study supports the use of the IFG cut-point at 6.1 mmol/l.     

The UK Diabetes Research Network--an opportunity and a challenge.

The Department of Health has funded a national diabetes network to support clinical research. The network will facilitate recruitment into clinical trials and has been widely welcomed by clinicians. However, if the network is to reach its full potential, all those involved will need to advocate a change in attitude towards clinical trials and research, encouraging participation and contribution of data. Clinicians need to be willing to take a proactive view about research studies, and to encourage patients to adopt a positive and altruistic attitude towards trial participation. The future of trials and other important clinical research in the UK may depend on it.     

Time and cost involved in the care of newly registered patients with diabetes mellitus and other lifestyle diseases at diabetes clinics in Japan (JDDM 4).

AIMS: To study the time and cost involved in the care of newly registered outpatients with Type 2 diabetes mellitus (DM), compared with patients with hypertension and/or hyperlipidaemia (HTL). METHODS: A total of 313 patients with DM and 58 patients with HTL without diabetes were registered on their first visits to 11 diabetes clinics across Japan. The time and cost involved in their care was recorded over the following 5 months. RESULTS: In the first 3 months, there was an extensive time commitment to both groups. The time spent by physicians was 1.5 times longer for DM than for HTL. The total care time spent by all the care providers for DM was twice that for HTL. The cost of DM care was twice that for HTL, with the cost of medicines excluded. However, half of the cost for DM was for laboratory tests. When these were excluded, and the remaining cost divided by the time spent, the amount for DM was half of that for HTL. Over the 5 months, mean glycated haemoglobin (HbA(1c)) in DM patients improved from 8.0% to 6.5%, and 72% of DM patients achieved the glycaemic target of HbA(1c) < or = 6.5%. CONCLUSIONS: DM care in a diabetes clinic requires a great deal more time and resources than HTL to achieve the best outcome. An educational system for self care, presently lacking in the primary care setting in Japan, would improve glycaemic control for DM patients in the community.     

社区人群糖尿病知识知晓率的描述性及分析性研究

目的了解社区人群对糖尿病知识知晓情况,为城镇居民进行糖尿病干预研究提供依据.方法对广州市荔湾区25岁以上常住居民进行随机抽样问卷,对资料作描述性和分析性研究.结果糖尿病知识知晓情况在年龄、性别、文化程度、糖尿病家族史、糖尿病患病史分布上有显著性差异.多因素分析显示:性别、年龄、文化程度、糖尿病家族史、糖尿病患病史、体力劳动强度、脑力劳动强度、收缩压与糖尿病知识知晓率密切相关,其比值比分别为1.239,0.990,1.223,2.752,1.897,1.373,0.916,0.884和0.996.结论该地区人群的糖尿病知识知晓率较低,要广泛开展全民特别是老年人、男性和文化程度较低人群的糖尿病知识宣传教育.     

妊娠期糖耐量受损与妊娠结局的关系

①目的　探讨妊娠期糖耐量受损 (GIGT)对妊娠结局的影响。②方法　以妊娠期GIGT孕妇 1 31例(GIGT组 ) ,妊娠期糖尿病 (GDM)孕妇 1 6 6例 (GDM组 ) ,糖耐量正常孕妇 1 6 0例 (正常对照组 )为研究对象 ,对孕妇及其围生儿结局进行对比研究。③结果　GIGT组及GDM组妊娠高血压综合征、巨大儿、羊水过多、胎膜早破、剖宫产及新生儿疾病发生情况均高于对照组 (χ2 =4 .0 2～ 81 .31 ,P <0 .0 5、0 .0 1 )。④结论　GIGT对妊娠可造成不同程度的危害 ,GIGT是影响孕妇及围生儿结局的重要因素。对妊娠期GIGT均应进行监测和处理     

佩兰二术汤治疗痰湿型2型糖尿病临床观察

目的观察佩兰二术汤治疗痰湿型2型糖尿病的临床疗效。方法37例2型糖尿病患者给予佩兰二术汤治疗,疗程2个月;观察其临床疗效和治疗前后空腹血糖(FPG)、血脂(TG、TC)的变化。结果临床治愈5例,好转29例,未愈3例,总有效率为91.89%;FPG、TC、TG明显降低(P<0.01)。结论佩兰二术汤治疗痰湿型2型糖尿病疗效确切。     

循环内皮细胞水平与糖尿病肾病的相关性及银杏达莫的干预作用

目的:探讨外周血循环内皮细胞(CEC)和糖尿病肾病(DN)的相关性,以及银杏达莫注射液在DN防治中的可能作用。方法:检测65例2型糖尿病患者24h尿白蛋白排泄率(UAER)及CEC数,分析两者的相关性。将UAER为30~300mg·d-1的45例患者随机分为两组,常规治疗组22例,进行常规降血糖、控制血压等治疗;银杏达莫治疗组23例,在常规治疗基础上静脉滴注银杏达莫注射液2周。比较两组治疗前后血糖、血压、UAER及CEC水平的变化。结果:单纯糖尿病(SDM)组和早期糖尿病肾病(EDN)组的外周血CEC水平比对照组(NC)显著性升高,并呈逐渐增高的趋势(P<0.01)。UAER与收缩压(SBP)、外周血CEC水平呈正相关(P<0.01)。EDN组中,银杏达莫治疗后UAER及CEC明显降低(P<0.01);而常规治疗组无明显变化。线性多元逐步回归分析表明,银杏达莫治疗后UAER的改变与CEC数的变化成正相关(P<0.01)。结论:血管内皮细胞(VEC)损伤在DN发生发展中起重要作用,银杏达莫对VEC的保护作用可能是其延缓DN发展的重要机制。